or Try an Advanced Search...

    Technical Analysis for INMB - INmune Bio Inc.

    Grade Last Price % Change Price Change
    C 10.48 -6.26% -0.70
    INMB closed down 6.26 percent on Wednesday, May 8, 2024, on approximately normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Down Down
    Historical INMB trend table...
    Date Alert Name Type % Chg
    Fell Below 20 DMA Bearish 0.00%
    Fell Below 50 DMA Bearish 0.00%
    Wide Bands Range Expansion 0.00%
    Down 3 Days in a Row Weakness 0.00%
    Gapped Down Weakness 0.00%
    50 DMA Support Bullish -6.26%
    Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -6.26%
    NR7 Range Contraction -6.26%
    Earnings Movers Other -6.26%
    Wide Bands Range Expansion -6.26%
    Older End-of-Day Signals for INMB ...

       Recent Intraday Alerts

    Alert Time
    20 DMA Support about 19 hours ago
    Fell Below 20 DMA about 21 hours ago
    Down 5% about 22 hours ago
    60 Minute Opening Range Breakdown about 22 hours ago
    Down 3% about 22 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    INMB Chart by TradingView
    Basic chart:

    Profile

    INmune Bio, Inc. is a clinical-stage biotechnology company developing therapies targeting the innate immune system in cancer. INmune Bio is developing two products platforms that reengineer the patient’s innate immune system’s response to their cancer, INKmune and INB03. INKmune is a Natural Killer (NK) cell therapeutic that primes the patient’s NK cells to attack developing disease. INB03 inhibits myeloid derived suppressor cells (MDSC), which often cause resistance to immunotherapy, such as anti-PD1 checkpoint inhibitors. INmune Bio’s product platforms target residual disease and utilize a precision medicine approach for treatment of a wide variety of hematologic malignancies and solid tumors.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Cancer Disease Solid Tumors Immune System Immunotherapy Cancer Treatment Precision Medicine Hematologic Malignancies Checkpoint Inhibitor Tumors Of The Hematopoietic And Lymphoid Tissues Residual Disease

    Is INMB a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 30 INmune Bio provides update on Alzheimer's candidate XPro
    Apr 30 INmune Bio Inc. Provides Update on Two Patients from the Phase 1b Alzheimer’s Disease Trial who Continue to Receive XPro™ Under Compassionate Use for Over Three Years
    Apr 29 INmune Bio Inc. Completes First Cohort and Initiates Second Cohort of Phase 1/2 Study of INKmune™ Natural Killer Cell Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer
    Apr 26 INmune Bio Independent Director Acquires 80% More Stock
    Apr 25 INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
    Apr 23 INmune Bio Inc. Announces 24-Month Stability Validation of XPro™ for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay
    Apr 22 INmune Bio rises 2%, on $4.5M direct offering
    Apr 22 INmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through Registered Direct Offering with Officers, Employees and Directors Purchasing Approximately 20% of the Offering
    Apr 22 INmune Bio: An Opportunity In The Freefall (Rating Upgrade)
    Apr 8 INmune Bio Inc. Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024
    See more INMB news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 14.74
    52 Week Low 6.5092
    Average Volume 120,706
    200-Day Moving Average 9.70
    50-Day Moving Average 11.11
    20-Day Moving Average 10.50
    10-Day Moving Average 11.29
    Average True Range 0.90
    RSI (14) 46.52
    ADX 18.8
    +DI 19.52
    -DI 19.19
    Chandelier Exit (Long, 3 ATRs) 10.03
    Chandelier Exit (Short, 3 ATRs) 10.99
    Upper Bollinger Bands 12.62
    Lower Bollinger Band 8.37
    Percent B (%b) 0.5
    BandWidth 40.51
    MACD Line 0.09
    MACD Signal Line 0.00
    MACD Histogram 0.0841
    Fundamentals Value
    Market Cap 188.87 Million
    Num Shares 18 Million
    EPS -1.52
    Price-to-Earnings (P/E) Ratio -6.89
    Price-to-Sales 971.08
    Price-to-Book 4.86
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 12.07
    Resistance 3 (R3) 12.20 11.80 11.81
    Resistance 2 (R2) 11.80 11.40 11.74 11.72
    Resistance 1 (R1) 11.14 11.14 10.94 11.01 11.63
    Pivot Point 10.74 10.74 10.64 10.68 10.74
    Support 1 (S1) 10.08 10.34 9.88 9.95 9.33
    Support 2 (S2) 9.68 10.08 9.62 9.24
    Support 3 (S3) 9.02 9.68 9.16
    Support 4 (S4) 8.89